Stay updated with breaking news from Sight Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for
Press Release GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update EMA oral presentation... | April 20, 2023
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for
Efforts to reduce cash burn in 2023 while securing LUMEVOQ manufacturing and preparing for commercial launch in Europe in H1 2024 PPQ campaign to start early May 2023 with results expected